2b (significantly (p = 0.009) from 10 mM of APAP with HMGB1 supernatant concentration at 56.6 1.74 ng/ml)
Evidence and Clinical Data# Alprostadil Clinical Evidence# Alprostadil has the more extensive evidence base, reflecting three decades of clinical use: Intracavernosal efficacy response rates (defined as erection sufficient for intercourse) exceed 80% across diverse ED populations, including men with diabetes, cardiovascular disease, post-prostatectomy status, and spinal cord injury MUSE efficacy the intraurethral formulation shows lower response rates (approximately 43% successful intercourse) but provides a needle-free alternative PDE5 inhibitor failures alprostadil is effective in approximately 50-60% of men who do not respond to oral PDE5 inhibitors, making it the standard second-line therapy Long-term data studies with follow-up exceeding 5 years demonstrate sustained efficacy, though dropout rates of 30-50% reflect the burden of injection-based treatment Combination data alprostadil can be combined with PDE5 inhibitors or other vasoactive agents (papaverine, phentolamine in "trimix" formulations) for refractory cases PT-141 Clinical Evidence# PT-141's clinical data spans both female and male populations: RECONNECT trials (female) two Phase 3 pivotal trials in premenopausal women with HSDD showed statistically significant improvements in the Female Sexual Function Index desire domain and reductions in distress scores compared to placebo
For instance, the cyclin-dependent kinase inhibitor p21, which is a p53-regulated gene product with pro-survival properties, has been shown to associate with the DLG motif of Nrf2 (OReilly, 2005)
The study by Ruggeri et al
Engelmann C, Habtesion A, Hassan M, Kerbert AJ, Hammerich L, Novelli S, et al
